# A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

> **NCT06615050** · PHASE3 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 572 (estimated)

## Conditions studied

- Graft-versus-host Disease (GVHD)

## Interventions

- **DRUG:** Tacrolimus (Tac)
- **DRUG:** Methotrexate (MTX)
- **DRUG:** Ruxolitinib (Rux)
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate mofetil (MMF)

## Key facts

- **NCT ID:** NCT06615050
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-02
- **Primary completion:** 2031-01-17
- **Final completion:** 2031-01-17
- **Target enrollment:** 572 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615050, "A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06615050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*